Former boxer David Haye has launched a surprising new career creating a brand of AI therapy to help people quit smoking. The "Combustion Reduction Programme" aims to help smokers gradually reduce their smoking over a few months.

The $30 million toe in the water

Haye's venture, SNUK AI, has set up shop with a passionate speech on its home page, claiming that the programme can help people quit smoking for free. The former boxer, known for his love of cigars , is now betting big on AI to tackle addiction.

Haye's foray into AI therapy raises questions about the effectiveness of tech in tackilng addiction. While AI has shown promise in various fieds, its application in smoking cessation is still largely untested.

An echo of Sydney's 2024 institutional buy-up

Haye's decision to launch an AI therapy programme echoes the 2024 institutional buy-up in Sydney, where investors poured millions into tech startups. however, the success of such ventures is often short-lived, and the market remains skeptical about the long-term viability of AI-driven solutions.

The Combustion Reduction Programme's free model also raises concerns about the sustainability of the business. With no clear revenue streams, it remains to be seen how Haye plans to fund the venture.

Who is the unnamed buyer?

Despite the programme's lofty claims, the identity of the unnamed buyer remains a mystery. Haye's decision to keep the buyer anonymous has sparked speculation about the true intentions behind the venture.

As the market continues to watch with bated breath, one thing is certain: Haye's gamble on AI therapy is a high-stakes game that could either pay off or leave him with a smoking hole in his pocket .

What auditors flagged in the May filing

A review of SNUK AI's May filing reveals a lack of transparency about the programme's funding and revenue streams. Auditors have flagged concerns about the company's financials, citing a lack of clarity on how the programme will generate revenue.

With the stakes high and the market watching closely,Haye's AI therapy programme is a case study in the risks and rewards of innovation.